Alpha Tau Medical公司公布了其Alpha DaRT技术联合帕博利珠单抗（Pembrolizumab）治疗晚期实体瘤患者的临床数据。结果显示，患者的中位总生存期（OS）达到18.2个月，中位无进展生存期（PFS）为5.4个月。这一数据为该联合疗法的进一步开发提供了积极的信号。
Alpha Tau Medical公司公布了其Alpha DaRT技术联合帕博利珠单抗（Pembrolizumab）治疗晚期实体瘤患者的临床数据。结果显示，患者的中位总生存期（OS）达到18.2个月，中位无进展生存期（PFS）为5.4个月。这一数据为该联合疗法的进一步开发提供了积极的信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.